FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311344042> ?p ?o ?g. }

• W4311344042 abstract "Purpose: To establish a pharmacist-led olaparib follow-up program for ovarian cancer patients, provide patient education, get information on adverse drug reactions (ADRs), and identify and manage drug-related problems. Methods: Ambulatory adult patients with ovarian cancer receiving olaparib were enrolled. At least one follow-up session was conducted by clinical pharmacists. Pharmacists collected data on the type and grade of ADRs, drug adherence, olaparib dosing, concomitant medications, and pharmacists' suggestions. Results: 83 patients were enrolled with the median age of 58. The average number of the follow-up sessions provided to each patient was 1.31, and the average duration of each follow-up was 17.78 min. The olaparib starting dose for most patients (97.59%) was 600 mg/d. 36.14% of the patients had missed olaparib doses and 27.71% of the patients had dose adjustments due to ADRs. The most common ADRs (incidence≥10%) were: fatigue (40.96%), anemia (36.14%), leukopenia (36.14%), nausea (28.92%), thrombocytopenia (16.87%), anorexia (16.87%), dyspepsia (15.66%). The tolerability profiles were generally similar between patients treated for first-line maintenance and those treated for recurrence maintenance (p > .05). There were 42% of the patients who were concomitantly taking medications without exact chemical contents (such as formulated Chinese medicines and Chinese decoctions), and common types of concomitant medications with exact drug names were antihypertensive, anti-hyperglycemic, and anti-hyperlipidemic medications. The pharmacists identified 4 clinically significant drug-drug interactions (DDIs) in two patients. Pharmacists made 196 suggestions mainly related to rational use of the medications and management of ADRs. Conclusion: The study provides the first report about pharmacist-led follow-up service for olaparib. The types of ADRs were similar to those previously observed in clinical trials, and the profiles of ADRs in different types of patients (first-line maintenance vs. recurrence maintenance) were also similar. Pharmacists identified drug-related problems (such as adherence, DDIs and management of ADRs) and offer suggestions for the patients." @default.
• W4311344042 created "2022-12-25" @default.
• W4311344042 creator A5013178268 @default.
• W4311344042 creator A5014198028 @default.
• W4311344042 creator A5017666606 @default.
• W4311344042 creator A5031810848 @default.
• W4311344042 creator A5032423839 @default.
• W4311344042 creator A5064101924 @default.
• W4311344042 creator A5084650592 @default.
• W4311344042 creator A5086272660 @default.
• W4311344042 date "2022-12-13" @default.
• W4311344042 modified "2023-10-18" @default.
• W4311344042 title "Pharmacist-led olaparib follow-up service for ambulatory ovarian cancer patients: A prospective study in a tertiary specialized cancer hospital in China" @default.
• W4311344042 cites W205259117 @default.
• W4311344042 cites W2096118581 @default.
• W4311344042 cites W2101907683 @default.
• W4311344042 cites W2137665561 @default.
• W4311344042 cites W2139062201 @default.
• W4311344042 cites W2139095012 @default.
• W4311344042 cites W2273769772 @default.
• W4311344042 cites W2533000199 @default.
• W4311344042 cites W2790121894 @default.
• W4311344042 cites W2892860186 @default.
• W4311344042 cites W2896628407 @default.
• W4311344042 cites W2896857408 @default.
• W4311344042 cites W2897430921 @default.
• W4311344042 cites W2918230069 @default.
• W4311344042 cites W2940149538 @default.
• W4311344042 cites W2990693468 @default.
• W4311344042 cites W3026822086 @default.
• W4311344042 cites W3030566019 @default.
• W4311344042 cites W3034673326 @default.
• W4311344042 cites W3037488822 @default.
• W4311344042 doi "https://doi.org/10.3389/fphar.2022.1037726" @default.
• W4311344042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36588742" @default.
• W4311344042 hasPublicationYear "2022" @default.
• W4311344042 type Work @default.
• W4311344042 citedByCount "0" @default.
• W4311344042 crossrefType "journal-article" @default.
• W4311344042 hasAuthorship W4311344042A5013178268 @default.
• W4311344042 hasAuthorship W4311344042A5014198028 @default.
• W4311344042 hasAuthorship W4311344042A5017666606 @default.
• W4311344042 hasAuthorship W4311344042A5031810848 @default.
• W4311344042 hasAuthorship W4311344042A5032423839 @default.
• W4311344042 hasAuthorship W4311344042A5064101924 @default.
• W4311344042 hasAuthorship W4311344042A5084650592 @default.
• W4311344042 hasAuthorship W4311344042A5086272660 @default.
• W4311344042 hasBestOaLocation W43113440421 @default.
• W4311344042 hasConcept C104317684 @default.
• W4311344042 hasConcept C121608353 @default.
• W4311344042 hasConcept C126322002 @default.
• W4311344042 hasConcept C182979987 @default.
• W4311344042 hasConcept C185592680 @default.
• W4311344042 hasConcept C197934379 @default.
• W4311344042 hasConcept C2778375690 @default.
• W4311344042 hasConcept C2779384505 @default.
• W4311344042 hasConcept C2779962180 @default.
• W4311344042 hasConcept C2780427987 @default.
• W4311344042 hasConcept C55493867 @default.
• W4311344042 hasConcept C71924100 @default.
• W4311344042 hasConcept C82381507 @default.
• W4311344042 hasConceptScore W4311344042C104317684 @default.
• W4311344042 hasConceptScore W4311344042C121608353 @default.
• W4311344042 hasConceptScore W4311344042C126322002 @default.
• W4311344042 hasConceptScore W4311344042C182979987 @default.
• W4311344042 hasConceptScore W4311344042C185592680 @default.
• W4311344042 hasConceptScore W4311344042C197934379 @default.
• W4311344042 hasConceptScore W4311344042C2778375690 @default.
• W4311344042 hasConceptScore W4311344042C2779384505 @default.
• W4311344042 hasConceptScore W4311344042C2779962180 @default.
• W4311344042 hasConceptScore W4311344042C2780427987 @default.
• W4311344042 hasConceptScore W4311344042C55493867 @default.
• W4311344042 hasConceptScore W4311344042C71924100 @default.
• W4311344042 hasConceptScore W4311344042C82381507 @default.
• W4311344042 hasFunder F4320321001 @default.
• W4311344042 hasLocation W43113440421 @default.
• W4311344042 hasLocation W43113440422 @default.
• W4311344042 hasLocation W43113440423 @default.
• W4311344042 hasLocation W43113440424 @default.
• W4311344042 hasOpenAccess W4311344042 @default.
• W4311344042 hasPrimaryLocation W43113440421 @default.
• W4311344042 hasRelatedWork W2147892042 @default.
• W4311344042 hasRelatedWork W2461919318 @default.
• W4311344042 hasRelatedWork W2796194059 @default.
• W4311344042 hasRelatedWork W2899252745 @default.
• W4311344042 hasRelatedWork W2900951833 @default.
• W4311344042 hasRelatedWork W2901275087 @default.
• W4311344042 hasRelatedWork W3006434046 @default.
• W4311344042 hasRelatedWork W3013297216 @default.
• W4311344042 hasRelatedWork W3190196624 @default.
• W4311344042 hasRelatedWork W4224221368 @default.
• W4311344042 hasVolume "13" @default.
• W4311344042 isParatext "false" @default.
• W4311344042 isRetracted "false" @default.
• W4311344042 workType "article" @default.